Search

You searched for "Botulinum toxin"

5 results found

Botulinum toxin – from the sausage poison to urology

4 May 2023 | | Functional Urology, Infection
Botulinum toxin is the first biological toxin to be licensed for use in treating human disease and since its first therapeutic use in the early 1980s for strabismus has become widely used in the fields of ophthalmology, cosmetic surgery, migraine...

Ten years of experience with intravesical and intrasphincteric botulinum toxin A in children

1 July 2017 | | Paediatric Urology | Botulinum toxin, Detrusor overactivity, Intrasphincteric injection, Intravesical injection, Paediatric
This is one of the longest follow-up studies of botulinum toxin A usage in children with bladder dysfunction in the paediatric literature. Fifty-three children had Botox® (Allergan) injected for a variety of reasons (spina bifida – 18, acquired cord injury...

Retention after Botox therapy in OAB

1 January 2016 | | Functional Urology | Botox, complication, intermittent catheterization, post-void residual
Treatment of overactive bladder (OAB) has a wide spectrum. The first step is lifestyle modifications, the second step is pharmacotherapy and the third line is intradetrusor injections with Botox®. This retrospective study is from Tennessee, USA in non-neurogenic and refractory...
The Journal of Urology cover image.

Botox® instillation into the bladder

4 May 2023 | | Basic Science Research, Functional Urology, Infection, Neurourology | botulinum toxins, overactive, type A, urinary bladder, urinary incontinence
Patients with refractory overactive bladder (OAB) may be offered OnabotulinumtoxinA (Botox®) as one of the third-line options. Given the invasive nature of requiring cystoscopy, injections via a needle and local anaesthesia, it would be simpler, more convenient and more accessible...

Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators

11 July 2023 | | Functional Urology
Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...